CenterBook Partners LP Raises Stake in Illumina, Inc. (NASDAQ:ILMN)

CenterBook Partners LP grew its holdings in Illumina, Inc. (NASDAQ:ILMNFree Report) by 176.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 70,328 shares of the life sciences company’s stock after acquiring an additional 44,883 shares during the quarter. Illumina accounts for 1.2% of CenterBook Partners LP’s portfolio, making the stock its 7th largest holding. CenterBook Partners LP’s holdings in Illumina were worth $9,792,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Annis Gardner Whiting Capital Advisors LLC acquired a new position in Illumina in the 3rd quarter valued at approximately $30,000. VisionPoint Advisory Group LLC raised its stake in shares of Illumina by 344.6% in the third quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock valued at $34,000 after purchasing an additional 193 shares in the last quarter. Wetzel Investment Advisors Inc. bought a new position in Illumina in the fourth quarter worth $37,000. Gradient Investments LLC boosted its stake in Illumina by 375.0% during the fourth quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock worth $40,000 after buying an additional 225 shares in the last quarter. Finally, North Star Investment Management Corp. increased its holdings in Illumina by 183.0% in the 4th quarter. North Star Investment Management Corp. now owns 300 shares of the life sciences company’s stock valued at $42,000 after buying an additional 194 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ILMN. Jefferies Financial Group assumed coverage on shares of Illumina in a research note on Monday, June 3rd. They set a “hold” rating and a $115.00 price target for the company. TD Cowen lowered their price target on Illumina from $140.00 to $122.00 and set a “hold” rating on the stock in a research report on Thursday. Robert W. Baird increased their target price on shares of Illumina from $125.00 to $128.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Stephens restated an “overweight” rating and issued a $170.00 price target on shares of Illumina in a research report on Tuesday, May 7th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $253.00 price objective on shares of Illumina in a report on Tuesday, April 9th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $161.24.

Check Out Our Latest Analysis on Illumina

Illumina Trading Down 0.9 %

NASDAQ ILMN traded down $1.02 during trading hours on Friday, hitting $113.70. The company’s stock had a trading volume of 2,850,090 shares, compared to its average volume of 2,057,189. The stock has a fifty day moving average of $116.80 and a 200 day moving average of $126.94. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.26. Illumina, Inc. has a twelve month low of $89.00 and a twelve month high of $212.49. The firm has a market capitalization of $18.11 billion, a P/E ratio of -13.95 and a beta of 1.20.

Illumina (NASDAQ:ILMNGet Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.05. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The company had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.05 billion. During the same quarter in the prior year, the business posted $0.08 EPS. The firm’s quarterly revenue was down 1.0% on a year-over-year basis. Equities research analysts forecast that Illumina, Inc. will post 0.88 earnings per share for the current fiscal year.

About Illumina

(Free Report)

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Recommended Stories

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with's FREE daily email newsletter.